Poxel Management

Management criteria checks 3/4

Poxel's CEO is Thomas Kuhn, appointed in Mar 2009, has a tenure of 15.17 years. total yearly compensation is €852.11K, comprised of 35.2% salary and 64.8% bonuses, including company stock and options. directly owns 4.37% of the company’s shares, worth €1.03M. The average tenure of the management team and the board of directors is 15.3 years and 9.2 years respectively.

Key information

Thomas Kuhn

Chief executive officer

€852.1k

Total compensation

CEO salary percentage	35.2%
CEO tenure	15.2yrs
CEO ownership	4.4%
Management average tenure	15.3yrs
Board average tenure	9.2yrs

Recent management updates

Recent updates

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Mar 27

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

May 07

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 16

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

Nov 17

CEO Compensation Analysis

How has Thomas Kuhn's remuneration changed compared to Poxel's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€38m
Dec 31 2022	€852k	€300k	-€31m
Sep 30 2022	n/a	n/a	-€30m
Jun 30 2022	n/a	n/a	-€29m
Mar 31 2022	n/a	n/a	-€26m
Dec 31 2021	€1m	€296k	-€24m
Sep 30 2021	n/a	n/a	-€26m
Jun 30 2021	n/a	n/a	-€28m
Mar 31 2021	n/a	n/a	-€30m
Dec 31 2020	€1m	€271k	-€32m
Sep 30 2020	n/a	n/a	-€30m
Jun 30 2020	n/a	n/a	-€28m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€478k	€230k	-€26m
Sep 30 2019	n/a	n/a	-€21m
Jun 30 2019	n/a	n/a	-€16m
Mar 31 2019	n/a	n/a	-€7m
Dec 31 2018	€433k	€206k	€1m
Sep 30 2018	n/a	n/a	-€2m
Jun 30 2018	n/a	n/a	-€5m
Mar 31 2018	n/a	n/a	-€14m
Dec 31 2017	€489k	€191k	-€22m

Compensation vs Market: Thomas's total compensation ($USD909.11K) is above average for companies of similar size in the French market ($USD324.51K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.

CEO

Thomas Kuhn

15.2yrs

Tenure

€852,112

Compensation

Mr. Thomas Kuhn, PharmD, MBA co-founded Poxel SA in 2009 and serves as its Chief Executive Officer and its Director since June 23, 2010. Mr. Kuhn joined Merck Serono in 2000, where he held various position...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Kuhn	Co-Founder	15.2yrs	€852.11k	4.37% € 1.0m
Sébastien Bolze	Co-Founder	15.3yrs	no data	no data
Pascale Fouqueray-Grellier	Co-Founder and Executive VP of Clinical Development & Regulatory Affairs	15.3yrs	no data	no data
Sophie Hallakou-Bozec	Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication	15.3yrs	no data	no data
Arthur Rouille	Investor Relations Officer	no data	no data	no data
Quentin Durand	Executive VP	4.7yrs	no data	no data
Sylvie Bertrand	Vice President of Human Resources	2.6yrs	no data	no data

15.3yrs

Average Tenure

Experienced Management: POXEL's management team is seasoned and experienced (15.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Kuhn	Co-Founder	13.9yrs	€852.11k	4.37% € 1.0m
Richard Kender	Independent Director	9.3yrs	€108.06k	no data
Harold Lebovitz	Member of Scientific Advisory Board	no data	no data	no data
Pascale Boissel	Independent Director	9.2yrs	€74.00k	no data
Mohammed Baluch	Independent Chairman of the Board	11.6yrs	€105.06k	no data
Ralph Defronzo	Member of Scientific Advisory Board	5.3yrs	no data	no data
Masato Kasuga	Member of Scientific Advisory Board	5.3yrs	no data	no data
John Amatruda	Member of Scientific Advisory Board	no data	no data	no data
Wataru Ogawa	Member of Scientific Advisory Board	no data	no data	no data
Kohjiro Ueki	Member of Scientific Advisory Board	no data	no data	no data
Hirotaka Watada	Member of Scientific Advisory Board	no data	no data	no data
Kohei Kaku	Member of Scientific Advisory Board	5.3yrs	no data	no data

9.2yrs

Average Tenure

Experienced Board: POXEL's board of directors are considered experienced (9.2 years average tenure).

Poxel Management

Management criteria checks 3/4

Key information

Recent management updates

Poxel S.A., Annual General Meeting, Jun 21, 2023

Insufficient new directors

Poxel S.A., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

New major risk - Share price stability

First half 2023 earnings released

Poxel S.A. to Report Q2, 2023 Results on Sep 26, 2023

Consensus revenue estimates decrease by 43%

Poxel S.A., Annual General Meeting, Jun 21, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 32%

Poxel S.A. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Consensus forecasts updated

First half 2022 earnings released

Poxel S.A. Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

Price target decreased to €11.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Poxel S.A. Announces Pxl065 and Pxl770 Granted Orphan Drug Designation from the U.S. Fda for X Linked Adrenoleukodystrophy

Poxel S.A., Annual General Meeting, Jun 21, 2022

Price target decreased to €13.43

Insufficient new directors

Poxel Announces PXL770 Wins FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

Insufficient new directors

Consensus revenue estimates fall by 28%

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Insufficient new directors

Poxel Announces PXL065 Granted FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

First half 2021 earnings released

POXEL SA Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases

Consensus forecasts updated

Poxel Presents Results of Two Clinical Studies on Its Direct Amp Kinase Activator, the Pxl770

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Poxel S.A. Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

Full year 2020 earnings released

New 90-day high: €7.62

Poxel S.A. Terminates Partnership Agreement with Metavant

Poxel S.A. to Report Q3, 2021 Results on Oct 20, 2021

Price target lowered to €15.83

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

Poxel Provides Update on Metavant Partnership with Imeglimin

Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting 2020

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

New 90-day high: €7.19

New 90-day low: €6.00

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

Poxel S.A. Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

First half earnings released

New 90-day low - €6.13

New 90-day low - €6.38

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure